Ultimovacs ASA: New share capital registered
November 13, 2023 04:46 ET
|
Ultimovacs ASA
Oslo, 13 November 2023, Ultimovacs ASA (the "Company") refers to the announcement published on 9 November 2023 regarding the issuance of new shares in connection with the Company's employee incentive...
Ultimovacs ASA: Share capital increase related to exercise of options
November 09, 2023 11:00 ET
|
Ultimovacs ASA
Oslo, 09 November 2023, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 960 through the issuance of 9,600 new shares, each with a...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 08, 2023 05:18 ET
|
Ultimovacs ASA
Oslo, 8 November 2023, Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 5,300 shares in the company at an average price of NOK 93.95 per share. Following this...
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
November 08, 2023 01:00 ET
|
Ultimovacs ASA
Oslo, November 8, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its third quarter 2023 results today. ...
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
November 02, 2023 03:00 ET
|
Ultimovacs ASA
Oslo, November 2, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its third...
Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma
November 02, 2023 02:00 ET
|
Ultimovacs ASA
The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of...
Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024
October 31, 2023 02:00 ET
|
Ultimovacs ASA
Patients in the INITIUM study are taking longer than expected to experience cancer progression. Reaching the number of progressing patients required for readout may take several months or even...
Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma
October 25, 2023 11:50 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, October 25, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that...
Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine
October 23, 2023 01:00 ET
|
Ultimovacs ASA
UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, met the study protocol’s predefined threshold for statistical significance and demonstrated a...
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma
October 17, 2023 12:01 ET
|
Ultimovacs ASA
UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall survival benefit with no added toxicities,...